CLINICAL TRIALS PROFILE FOR VOSORITIDE
✉ Email this page to a colleague
All Clinical Trials for VOSORITIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02055157 ↗ | A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia | Completed | BioMarin Pharmaceutical | Phase 2 | 2014-01-13 | This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia. |
NCT02724228 ↗ | A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) | Active, not recruiting | BioMarin Pharmaceutical | Phase 2 | 2016-01-26 | This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study. |
NCT03197766 ↗ | A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | Completed | BioMarin Pharmaceutical | Phase 3 | 2016-12-12 | The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia. |
NCT03424018 ↗ | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | Active, not recruiting | BioMarin Pharmaceutical | Phase 3 | 2017-12-12 | The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia |
NCT03583697 ↗ | A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia | Active, not recruiting | BioMarin Pharmaceutical | Phase 2 | 2018-05-23 | Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia. |
NCT03989947 ↗ | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia | Enrolling by invitation | BioMarin Pharmaceutical | Phase 2 | 2019-06-12 | This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VOSORITIDE
Condition Name
Clinical Trial Locations for VOSORITIDE
Trials by Country
Clinical Trial Progress for VOSORITIDE
Clinical Trial Phase
Clinical Trial Sponsors for VOSORITIDE
Sponsor Name